HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets genetic weakness in advanced breast cancer
Disease control TerminatedThis study tests a drug called fluzoparib, either alone or with another drug called camrelizumab, in people with a specific type of advanced breast cancer (HRD-positive, HER2-negative). The goal is to see if these treatments can shrink tumors or slow the cancer's growth. About 80…
Matched conditions: HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: wang shusen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill combo could delay advanced breast cancer progression
Disease control OngoingThis study tests whether a combination of two targeted pills (fluorizoparib and apatinib) works better than standard chemotherapy for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). About 200 participants will be randomly assigned to e…
Matched conditions: HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC